C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results

Renee C. Prins, Brooks L. Rademacher, Solange Mongoue-Tchokote, Joshi Alumkal, Julie Graff, Kristine M. Eilers, Tomasz (Tom) Beer

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

We previously reported that higher serum concentrations of C-reactive protein (CRP) are associated with shorter survival in men with castration-resistant prostate cancer (CRPC). To confirm this finding in an independent data set, we used 119 CRPC patients enrolled in 6 phase II clinical trials and examined the relationship of CRP, alkaline phosphatase, hemoglobin, age, ECOG PS, and prostate specific antigen (PSA) with survival. Median follow-up was 19.7 months (0.9-98.5 months), and 89% have died. After analyzing the form of the risk function using the generalized additive model method, univariate and multivariate Cox proportional hazard models were used to assess associations between baseline individual categorical and continuous variables. Quartiles of CRP were: 0-1.0, 1.1-4.9, 5.0-17.0, and 17.1-311 mg/L. In a Cox multivariate model, log 2 (CRP) (HR 1.106, P = 0.013) as well as hemoglobin and alkaline phosphatase were independently associated with survival, confirming that higher CRP is associated with shorter survival in CRPC. Since CRP is a marker of inflammation, this finding suggests that inflammation may play an important role in the natural history of advanced prostate cancer. CRP is a readily measurable biomarker that has the potential to improve prognostic models and should be validated in a prospective clinical trial.

Original languageEnglish (US)
Pages (from-to)33-37
Number of pages5
JournalUrologic Oncology: Seminars and Original Investigations
Volume30
Issue number1
DOIs
StatePublished - Jan 2012

Fingerprint

Castration
C-Reactive Protein
Prostatic Neoplasms
Survival
Proportional Hazards Models
Alkaline Phosphatase
Hemoglobins
Inflammation
Phase II Clinical Trials
Phosphoprotein Phosphatases
Prostate-Specific Antigen
Natural History
Biomarkers
Clinical Trials
Serum

Keywords

  • C-reactive protein
  • Inflammation
  • Prognosis
  • Prostate cancer
  • Survival

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC) : Confirmatory results. / Prins, Renee C.; Rademacher, Brooks L.; Mongoue-Tchokote, Solange; Alumkal, Joshi; Graff, Julie; Eilers, Kristine M.; Beer, Tomasz (Tom).

In: Urologic Oncology: Seminars and Original Investigations, Vol. 30, No. 1, 01.2012, p. 33-37.

Research output: Contribution to journalArticle

@article{47065716137f43e788068ebe6f246cf1,
title = "C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): Confirmatory results",
abstract = "We previously reported that higher serum concentrations of C-reactive protein (CRP) are associated with shorter survival in men with castration-resistant prostate cancer (CRPC). To confirm this finding in an independent data set, we used 119 CRPC patients enrolled in 6 phase II clinical trials and examined the relationship of CRP, alkaline phosphatase, hemoglobin, age, ECOG PS, and prostate specific antigen (PSA) with survival. Median follow-up was 19.7 months (0.9-98.5 months), and 89{\%} have died. After analyzing the form of the risk function using the generalized additive model method, univariate and multivariate Cox proportional hazard models were used to assess associations between baseline individual categorical and continuous variables. Quartiles of CRP were: 0-1.0, 1.1-4.9, 5.0-17.0, and 17.1-311 mg/L. In a Cox multivariate model, log 2 (CRP) (HR 1.106, P = 0.013) as well as hemoglobin and alkaline phosphatase were independently associated with survival, confirming that higher CRP is associated with shorter survival in CRPC. Since CRP is a marker of inflammation, this finding suggests that inflammation may play an important role in the natural history of advanced prostate cancer. CRP is a readily measurable biomarker that has the potential to improve prognostic models and should be validated in a prospective clinical trial.",
keywords = "C-reactive protein, Inflammation, Prognosis, Prostate cancer, Survival",
author = "Prins, {Renee C.} and Rademacher, {Brooks L.} and Solange Mongoue-Tchokote and Joshi Alumkal and Julie Graff and Eilers, {Kristine M.} and Beer, {Tomasz (Tom)}",
year = "2012",
month = "1",
doi = "10.1016/j.urolonc.2009.11.012",
language = "English (US)",
volume = "30",
pages = "33--37",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC)

T2 - Confirmatory results

AU - Prins, Renee C.

AU - Rademacher, Brooks L.

AU - Mongoue-Tchokote, Solange

AU - Alumkal, Joshi

AU - Graff, Julie

AU - Eilers, Kristine M.

AU - Beer, Tomasz (Tom)

PY - 2012/1

Y1 - 2012/1

N2 - We previously reported that higher serum concentrations of C-reactive protein (CRP) are associated with shorter survival in men with castration-resistant prostate cancer (CRPC). To confirm this finding in an independent data set, we used 119 CRPC patients enrolled in 6 phase II clinical trials and examined the relationship of CRP, alkaline phosphatase, hemoglobin, age, ECOG PS, and prostate specific antigen (PSA) with survival. Median follow-up was 19.7 months (0.9-98.5 months), and 89% have died. After analyzing the form of the risk function using the generalized additive model method, univariate and multivariate Cox proportional hazard models were used to assess associations between baseline individual categorical and continuous variables. Quartiles of CRP were: 0-1.0, 1.1-4.9, 5.0-17.0, and 17.1-311 mg/L. In a Cox multivariate model, log 2 (CRP) (HR 1.106, P = 0.013) as well as hemoglobin and alkaline phosphatase were independently associated with survival, confirming that higher CRP is associated with shorter survival in CRPC. Since CRP is a marker of inflammation, this finding suggests that inflammation may play an important role in the natural history of advanced prostate cancer. CRP is a readily measurable biomarker that has the potential to improve prognostic models and should be validated in a prospective clinical trial.

AB - We previously reported that higher serum concentrations of C-reactive protein (CRP) are associated with shorter survival in men with castration-resistant prostate cancer (CRPC). To confirm this finding in an independent data set, we used 119 CRPC patients enrolled in 6 phase II clinical trials and examined the relationship of CRP, alkaline phosphatase, hemoglobin, age, ECOG PS, and prostate specific antigen (PSA) with survival. Median follow-up was 19.7 months (0.9-98.5 months), and 89% have died. After analyzing the form of the risk function using the generalized additive model method, univariate and multivariate Cox proportional hazard models were used to assess associations between baseline individual categorical and continuous variables. Quartiles of CRP were: 0-1.0, 1.1-4.9, 5.0-17.0, and 17.1-311 mg/L. In a Cox multivariate model, log 2 (CRP) (HR 1.106, P = 0.013) as well as hemoglobin and alkaline phosphatase were independently associated with survival, confirming that higher CRP is associated with shorter survival in CRPC. Since CRP is a marker of inflammation, this finding suggests that inflammation may play an important role in the natural history of advanced prostate cancer. CRP is a readily measurable biomarker that has the potential to improve prognostic models and should be validated in a prospective clinical trial.

KW - C-reactive protein

KW - Inflammation

KW - Prognosis

KW - Prostate cancer

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84855691020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855691020&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2009.11.012

DO - 10.1016/j.urolonc.2009.11.012

M3 - Article

C2 - 20207556

AN - SCOPUS:84855691020

VL - 30

SP - 33

EP - 37

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 1

ER -